This is an additional confirmation for our long-term goal exploiting the mtDNA damage as a main object in the treatment of IR and targeting hOGG1 to mitochondria as a novel approach for treatment of obesity-induced IR and metabolic syndrome. Here, OGG1 is linked to obesity disorder.